Therapeutic approaches to non-Hodgkin’s lymphoma in the elderly patient

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Weisenburger DD. Epidemiology of non-Hodgkin’s lymphoma: recent findings regarding an emerging epidemic. Ann. Oncol.5(Suppl. 1), 19–24 (1994).
   PubMedGoogle Scholar
• SEER Cancer Statistics Review, 1975–2005. Ries LAG, Melbert D, Krapcho M et al. (Eds). National Cancer Institute, Bethesda, MD, USA (2008).
   Google Scholar
• Goss PE. Non-Hodgkin’s lymphomas in elderly patients. Leuk. Lymphoma10(3), 147–156 (1993).
   PubMed Web of Science ®Google Scholar
• d’Amore F, Brincker H, Christensen BE et al. Non-Hodgkin’s lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. The Danish LYEO-Study Group. Ann. Oncol.3(5), 379–386 (1992).
   PubMed Web of Science ®Google Scholar
• van Spronsen DJ, Janssen-Heijnen ML, Breed WP, Coebergh JW. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin’s disease and non-Hodgkin’s lymphoma, 1993–1996. Ann. Hematol.78(7), 315–319 (1999).
   PubMed Web of Science ®Google Scholar
• Balducci L, Extermann M. Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Cancer80(7), 1317–1322 (1997).
   PubMed Web of Science ®Google Scholar
• Lugtenburg PJ, Sonneveld P. Treatment of diffuse large B-cell lymphoma in the elderly: strategies integrating oncogeriatric themes. Curr. Oncol. Rep.10(5), 412–419 (2008).
   PubMedGoogle Scholar
• de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical review of available methods. J. Clin. Epidemiol.56(3), 221–229 (2003).
   PubMed Web of Science ®Google Scholar
• Balducci L, Extermann M. Cancer and aging. An evolving panorama. Hematol. Oncol. Clin. North Am.14(1), 1–16 (2000).
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Coiffier B. Lymphoma in older patients. J. Clin. Oncol.25(14), 1916–1923 (2007).
   PubMed Web of Science ®Google Scholar
• Effect of age on the characteristics and clinical behavior of non-Hodgkin’s lymphoma patients. The Non-Hodgkin’s Lymphoma Classification Project. Ann. Oncol.8(10), 973–978 (1997).
   PubMed Web of Science ®Google Scholar
• National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin’s Lymphoma Pathologic Classification Project. Cancer49(10), 2112–2135 (1982).
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Stein H et al. A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood84(5), 1361–1392 (1994).
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting – Airlie House, Virginia, November 1997. J. Clin. Oncol.17(12), 3835–3849 (1999).
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N. Engl. J. Med.329(14), 987–994 (1993).
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood109(5), 1857–1861 (2007).
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature403(6769), 503–511 (2000).
   PubMed Web of Science ®Google Scholar
• Lossos IS, Czerwinski DK, Alizadeh AA et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N. Engl. J. Med.350(18), 1828–1837 (2004).
   PubMed Web of Science ®Google Scholar
• Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl Acad. Sci. USA100(17), 9991–9996 (2003).
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood104(5), 1258–1265 (2004).
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W et al.; German Low Grade Lymphoma Study Group (GLSG), European Mantle Cell Lymphoma Network. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood111(2), 558–565 (2008).
   PubMed Web of Science ®Google Scholar
• Horning SJ. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin. Oncol.20(5 Suppl. 5), 75–88 (1993).
   PubMed Web of Science ®Google Scholar
• Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N. Engl. J. Med.311(23), 1471–1475 (1984).
   PubMed Web of Science ®Google Scholar
• Tsang RW, Gospodarowicz MK. Radiation therapy for localized low-grade non-Hodgkin’s lymphomas. Hematol. Oncol.23(1), 10–17 (2005).
   PubMed Web of Science ®Google Scholar
• Wilder RB, Jones D, Tucker SL et al. Long-term results with radiotherapy for stage I–II follicular lymphomas. Int. J. Radiat. Oncol. Biol. Phys.51(5), 1219–1227 (2001).
   PubMed Web of Science ®Google Scholar
• Tezcan H, Vose JM, Bast M, Bierman PJ, Kessinger A, Armitage JO. Limited stage I and II follicular non-Hodgkin’s lymphoma: the Nebraska Lymphoma Study Group experience. Leuk. Lymphoma34(3–4), 273–285 (1999).
   PubMed Web of Science ®Google Scholar
• Peterson BA, Petroni GR, Frizzera G et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J. Clin. Oncol.21(1), 5–15 (2003).
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Hagemeister FB, Romaguera JE et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J. Clin. Oncol.14(4), 1262–1268 (1996).
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood90(6), 2188–2195 (1997).
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol.16(8), 2825–2833 (1998).
   PubMed Web of Science ®Google Scholar
• Hainsworth JD. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma: interim follow-up of a multicenter Phase II trial. Semin. Oncol.29(1 Suppl. 2), 25–29 (2002).
   PubMed Web of Science ®Google Scholar
• Witzig TE, Vukov AM, Habermann TM et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin’s lymphoma: a Phase II trial in the North Central Cancer Treatment Group. J. Clin. Oncol.23(6), 1103–1108 (2005).
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Lamb MR, Rodriguez GI, Scroggin C Jr, Greco FA. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin’s lymphoma: Phase II trial. Clin. Lymphoma4(1), 36–42 (2003).
   PubMedGoogle Scholar
• Hainsworth JD, Litchy S, Burris HA 3rd et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin’s lymphoma. J. Clin. Oncol.20(20), 4261–4267 (2002).
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz SF, Cogliatti SB et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood103(12), 4416–4423 (2004).
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CsHOP chemotherapy. J. Clin. Oncol.17(1), 268–276(1999).
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J. Clin. Oncol.22(23), 4711–4716 (2004).
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Koryzna A, Mohr A et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J. Clin. Oncol.23(4), 694–704 (2005).
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Dreyling M, Repp R et al.; German Low-Grade Lymphoma Study Group. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood104(10), 3064–3071 (2004).
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood106(12), 3725–3732 (2005).
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J. Clin. Oncol.26(28), 4579–4586 (2008).
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood105(4), 1417–1423 (2005).
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J. Clin. Oncol.26(28), 4579–4586 (2008).
   PubMed Web of Science ®Google Scholar
• van Oers MH, Klasa R, Marcus RE et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized Phase III Intergroup trial. Blood108(10), 3295–3301 (2006).
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma – a randomized Phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol.23(6), 1088–1095 (2005).
   PubMed Web of Science ®Google Scholar
• Robinson KS, Williams ME, Cohen P et al. Bendamustine HCl (TREANDA™) treatment in combination with rituximab results in objective responses in patients with refractory/relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma: results from Phase II multicenter study (SDX-105–102). ASH Annual Meeting Abstracts. Blood106(11) (2005) (Abstract 923).
   PubMedGoogle Scholar
• Robinson KS, Williams ME, van der Jagt RH et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J. Clin. Oncol.26(27), 4473–4479 (2008).
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Heine K, Bodenstein H et al. Efficacy and safety of bendamustine and rituximab in the treatment of indolent and mantle cell lymphomas in older patients. ASCO Annual Meeting 2008. J. Clin. Oncol.26(Suppl. 15) (2008) (Abstract 8572).
   Google Scholar
• Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol.20(10), 2453–2463 (2002).
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Estes J, Zasadny KR et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood96(4), 1259–1266 (2000).
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Radford JA, Gregory SA et al. Re-treatment with I-131 tositumomab in patients with non-Hodgkin’s lymphoma who had previously responded to I-131 tositumomab. J. Clin. Oncol.23(31), 7985–7993 (2005).
   PubMed Web of Science ®Google Scholar
• Press OW, Unger JM, Braziel RM et al.; Southwest Oncology Group. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J. Clin. Oncol.24(25), 4143–4149 (2006).
   PubMed Web of Science ®Google Scholar
• Leonard JP, Coleman M, Kostakoglu L et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I131 tositumomab for untreated follicular lymphoma. J. Clin. Oncol.23(24), 5696–5704 (2005).
   PubMed Web of Science ®Google Scholar
• Shipley DL, Greco FA, Spigel DR. Rituximab with short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: update of a Minnie Pearl Cancer Research Network Phase II trial. ASCO Annual Meeting Proceedings. J. Clin. Oncol.23(16S) (2005) (Abstract 6577).
   PubMedGoogle Scholar
• Zinzani PL, Tani M, Fanti S et al. A Phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann. Oncol.19(4), 769–773 (2008).
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med.346(4), 235–242 (2002).
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J. Clin. Oncol.24(19), 3121–3127 (2006).
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Kloess M et al. German High-Grade Non-Hodgkin’s Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood104(3), 634–641 (2004).
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M et al.; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol.9(2), 105–116 (2008).
   PubMed Web of Science ®Google Scholar
• Spicer J, Smith P, Maclennan K et al. Long-term follow-up of patients treated with radiotherapy alone for early-stage histologically aggressive non-Hodgkin’s lymphoma. Br. J. Cancer90(6), 1151–1155 (2004).
   PubMed Web of Science ®Google Scholar
• Miller TP, Dahlberg S, Cassady JR et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N. Engl. J. Med.339(1), 21–26 (1998).
   PubMed Web of Science ®Google Scholar
• Miller TP, LeBlanc M, Spier CM, Chase EM, Fisher R. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin’s lymphoma: update of the Southwest Oncology Group (SWOG) randomized trial. ASH Annual Meeting. Blood98 (2001) (Abstract 724).
   Google Scholar
• Bonnet C, Fillet G, Mounier N et al.; Groupe d’Etude des Lymphomes de l’Adulte. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J. Clin. Oncol.25(7), 787–792 (2007).
   PubMed Web of Science ®Google Scholar
• Persky DO, Unger JM, Spier CM et al.; Southwest Oncology Group. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J. Clin. Oncol.26(14), 2258–2263 (2008).
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N. Engl. J. Med.328(14), 1002–1006 (1993).
   PubMed Web of Science ®Google Scholar
• Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J. Am. Geriatr. Soc.32(4), 269–273 (1984).
   PubMed Web of Science ®Google Scholar
• Vose JM, Armitage JO, Weisenburger DD et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin’s lymphoma. J. Clin. Oncol.6(12), 1838–1844 (1988).
   PubMed Web of Science ®Google Scholar
• Gottlieb AJ, Anderson JR, Ginsberg SJ et al. A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin’s lymphomas. Cancer and Leukemia Group B study 7851. Cancer66(9), 1888–1896 (1990).
   PubMed Web of Science ®Google Scholar
• Grogan L, Corbally N, Dervan PA, Byrne A, Carney DN. Comparable prognostic factors and survival in elderly patients with aggressive non-Hodgkin’s lymphoma treated with standard-dose adriamycin-based regimens. Ann. Oncol.5(Suppl.) 247–251 (1994).
   Google Scholar
• Campbell C, Sawka C, Franssen E, Berinstein NL. Delivery of full dose CHOP chemotherapy to elderly patients with aggressive non-Hodgkin’s lymphoma without G-CSF support. Leuk. Lymphoma35(1–2), 119–127 (1999).
   PubMed Web of Science ®Google Scholar
• Jacobson JO, Grossbard M, Shulman LN, Neuberg D. CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin’s lymphoma: a dose-intensity analysis. Clin. Lymphoma1(3), 211–217; discussion 218 (2000).
   PubMedGoogle Scholar
• Sonneveld P, de Ridder M, van der Lelie H et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin’s lymphoma using CHOP versus CNOP chemotherapy. J. Clin. Oncol.13(10), 2530–2539 (1995).
   PubMed Web of Science ®Google Scholar
• Liang R, Todd D, Chan TK, Chiu E, Lie A, Ho F. COPP chemotherapy for elderly patients with intermediate and high grade non-Hodgkin’s lymphoma. Hematol. Oncol.11(1), 43–50 (1993).
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Johnson DH, Frazier SR, Greco FA. Chronic daily administration of oral etoposide in refractory lymphoma. Eur. J. Cancer26(7), 818–821 (1990).
   PubMed Web of Science ®Google Scholar
• Hainsworth JD. Chronic administration of etoposide in the treatment of non-Hodgkin’s lymphoma. Leuk. Lymphoma10(Suppl.), 65–72 (1993).
   PubMedGoogle Scholar
• Young WA, Greco FA, Greer JP, Hainsworth JD. Aggressive non-Hodgkin’s lymphoma in the elderly: an effective, well-tolerated treatment regimen containing extended-schedule etoposide. J. Natl Cancer Inst.86(17), 1346–1347 (1994).
   PubMedGoogle Scholar
• Meyer RM, Browman GP, Samosh ML et al. Randomized Phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin’s lymphoma. J. Clin. Oncol.13(9), 2386–2393 (1995).
   PubMed Web of Science ®Google Scholar
• Bastion Y, Blay JY, Divine M et al. Elderly patients with aggressive non-Hodgkin’s lymphoma: disease presentation, response to treatment, and survival – a Groupe d’Etude des Lymphomes de l’Adulte study on 453 patients older than 69 years. J. Clin. Oncol.15(8), 2945–2953 (1997).
   PubMed Web of Science ®Google Scholar
• Tirelli U, Errante D, Van Glabbeke M et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin’s lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J. Clin. Oncol.16(1), 27–34 (1998).
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J. Clin. Oncol.23(18), 4117–4126 (2005).
   PubMed Web of Science ®Google Scholar
• Vose JM, Link BK, Grossbard ML et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J. Clin. Oncol.19(2), 389–397 (2001).
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J. Clin. Oncol.23(22), 5027–5033 (2005).
   PubMed Web of Science ®Google Scholar
• Coiffier B, Feugier P, Mounier N. Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients. ASCO Annual Meeting Proceedings. J. Clin. Oncol.25(18S) (2007) (Abstract 8009).
   Google Scholar
• Morrison VA, Weller EA, Habermann TM. Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL). ASCO Annual Meeting Proceedings. J. Clin. Oncol.25(18S) (2007) (Abstract 8011).
   Google Scholar
• Jabbour E, Chalhoub B, Suzan F et al. Outcome of elderly patients with aggressive non-Hodgkin’s lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: a low probability of cure. Leuk. Lymphoma45(7), 1391–1394 (2004).
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87–2 protocol – a groupe d’Etude des lymphomes de l’Adulte study. J. Clin. Oncol.18(16), 3025–3030 (2000).
   PubMed Web of Science ®Google Scholar
• Jantunen E. Autologous stem cell transplantation beyond 60 years of age. Bone Marrow Transplant.38(11), 715–720 (2006).
   PubMed Web of Science ®Google Scholar
• Jantunen E, Itala M, Juvonen E et al. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin’s lymphoma: a nation-wide analysis. Bone Marrow Transplant.37(4), 367–372 (2006).
   PubMed Web of Science ®Google Scholar
• Gopal AK, Rajendran JG, Gooley TA et al. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J. Clin. Oncol.25(11), 1396–1402 (2007).
   PubMed Web of Science ®Google Scholar
• Jantunen E, Canals C, Rambaldi A et al.; EBMT Lymphoma Working Party. Autologous stem cell transplantation in elderly patients (≥60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation Registry. Haematologica93(12), 1837–1842 (2008).
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Grossoeuvre A, Houot R et al. Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann. Oncol.19(4), 774–779 (2008).
   PubMed Web of Science ®Google Scholar
• Errante D, Bianco A, Aversa SM, Salvagno L; Non-Hodgkin’s Lymphoma Cooperative Study Group. Comment on: non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann. Oncol.19(7), 1359–1360 (2008).
   PubMedGoogle Scholar